1. Home
  2. PVLA vs NRXP Comparison

PVLA vs NRXP Comparison

Compare PVLA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • NRXP
  • Stock Information
  • Founded
  • PVLA 2015
  • NRXP 2015
  • Country
  • PVLA United States
  • NRXP United States
  • Employees
  • PVLA N/A
  • NRXP N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • NRXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • PVLA Health Care
  • NRXP Health Care
  • Exchange
  • PVLA Nasdaq
  • NRXP Nasdaq
  • Market Cap
  • PVLA 15.9M
  • NRXP 14.8M
  • IPO Year
  • PVLA N/A
  • NRXP N/A
  • Fundamental
  • Price
  • PVLA N/A
  • NRXP $1.50
  • Analyst Decision
  • PVLA
  • NRXP Strong Buy
  • Analyst Count
  • PVLA 0
  • NRXP 3
  • Target Price
  • PVLA N/A
  • NRXP $31.67
  • AVG Volume (30 Days)
  • PVLA 47.8K
  • NRXP 317.1K
  • Earning Date
  • PVLA 01-01-0001
  • NRXP 11-14-2024
  • Dividend Yield
  • PVLA N/A
  • NRXP N/A
  • EPS Growth
  • PVLA N/A
  • NRXP N/A
  • EPS
  • PVLA N/A
  • NRXP N/A
  • Revenue
  • PVLA N/A
  • NRXP N/A
  • Revenue This Year
  • PVLA N/A
  • NRXP N/A
  • Revenue Next Year
  • PVLA N/A
  • NRXP N/A
  • P/E Ratio
  • PVLA N/A
  • NRXP N/A
  • Revenue Growth
  • PVLA N/A
  • NRXP N/A
  • 52 Week Low
  • PVLA $6.20
  • NRXP $1.10
  • 52 Week High
  • PVLA $22.32
  • NRXP $7.33
  • Technical
  • Relative Strength Index (RSI)
  • PVLA N/A
  • NRXP 61.95
  • Support Level
  • PVLA N/A
  • NRXP $1.17
  • Resistance Level
  • PVLA N/A
  • NRXP $1.85
  • Average True Range (ATR)
  • PVLA 0.00
  • NRXP 0.13
  • MACD
  • PVLA 0.00
  • NRXP 0.04
  • Stochastic Oscillator
  • PVLA 0.00
  • NRXP 50.00

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: